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The article (Thornhill 2019) suggest higher rates of adverse events associated with penicillin 
V compared to amoxicillin in dental practice. There are several methodological errors and 
associated misinterpretation of data derived from the National Yellow Card Drug Analysis 
Profile (Yellow Card MHRA 2019; Sophie Reeve, Personal Communication). To quote from 
MHRA; 
“When using the Interactive Drug Analysis Profile, you should remember that: 
1. The likelihood of experiencing an adverse drug reaction when taking a medicine cannot be 
estimated from the data in the Interactive Drug Analysis Profile.... 
2. The existence of an adverse drug reaction report in the Interactive Drug Analysis Profile 
does not necessarily mean that the medicine has caused the reaction. 
3. It is not possible to compare the safety of different medicines by comparing the numbers 
presented in the Interactive Drug Analysis Profiles. Reporting rates can be influenced by 
many factors including the seriousness of the adverse drug reactions, their ease of recognition 
and the extent of use of a particular product. Reporting can also be stimulated by promotion 
and publicity about a product.” 
Furthermore, NHS digital data refers to NHS prescriptions in NHS practice in England only. 
The NHS digital prescribing data does not capture private prescriptions or from N Ireland, 
Wales or Scotland. The Yellowcard data is collated from all of the UK. In addition, it is 
inaccurate to state that private dental prescribing is insignificant.  The number of patients 
receiving private treatment is estimated to be around 33% in the UK (Burke et al., 2015)   
Private provision has increased since 2015 and Denplan, a private dental insurance provider, 
has 6,500 dentist members covering nearly 2 million patients. 
We recommend these study limitations are highlighted and that readers are made aware of the 
significant limitations in this manuscript.  
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